An immunogenicity, safety and post-marketing surveillance of a novel adsorbed human diploid cell rabies vaccine (Rabivax®) in Indian subjects

Human Vaccines

Volumn 4, Issue 4, 2008, Pages 275-279

  Sudarshan, M K ^a   Bhardwaj, S ^b   Mahendra, B J ^c   Sharma, H ^b   Sanjay, T V ^a   Ashwathnarayana, D H ^a   Bilagumba, Gangaboraiah ^a  

^a KEMPEGOWDA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Serum Institute of India   (India)

^c Mandya Institute of Medical Sciences   (India)

Author keywords

Cell culture rabies vaccine; Human diploid cell rabies vaccine; Rabies in india; Rabivax (adsorbed)

Indexed keywords

HUMAN DIPLOID CELL RABIES VACCINE; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; RABIES VACCINE; RABIVAX;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOG BITE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; INDIA; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; POSTMARKETING SURVEILLANCE; RABIES; UNSPECIFIED SIDE EFFECT;

EID: 50849103665     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.4.5588     Document Type: Article

References (11)

1. Association for Prevention and Control of Rabies in India. Assessing Burden of Rabies in India, WHO sponsored national multi-centric rabies survey, May 2004, KIMS, Bangalore, India (www.apcri.org).
2. World Health Organization. WHO expert consultation on rabies, first report, Technical Report Series, 931, 2005, Geneva, Switzerland.
3. World Health Organization. Rabies Vaccines. WHO position paper, Weekly Epidemiological Record, No. 14, 5th April 2002, Geneva, Switzerland.
4. Haslett C, Chilvers ER, Boon NA, Nicki R. Davidson's principles and practice of medicine, Ed. Colledge Int ed John A Huner. 50th Ed Rabies, Churchill Living Stone, Edinburgh. 2002; 1198.
5. Serum Institute of India. Rabivax, Product monograph, 2004, Pune, India.
6. Meslin FX, Kaplan MM, Koprowski H. Laboratory techniques in rabies, ed. World Health Organization. Geneva, Switzerland; 1996.
7. Rabies vaccine in AHFS Drug Information. 2007; 3408-14;
8. WHO recommendations on rabies post-exposure treatment and the correct technique of intra-dermal immunization against rabies. World Health Organization. Geneva, Switzerland. 1997.
9. Bahmanyar M, Fayaz A, Noor Salehi S, Mohammadi M and Koprowski H. Successful protection of humans exposed to rabies infection. Post-exposure treatment with the new human diploid cell rabies vaccine and anti-rabies serum, JAMA, 1976; 236:2751.
10. Thongcharoen P, Wasi C, Chavanich L. Experiences with human diploid cell rabies vaccine. Pre and Post-exposure treatments of rabies in Thailand. Presented at the seminar on important tropical diseases in South East Asia, November 3-8, 1980, Bangkok, Thailand.
11. Mean F, Steck F and Tanner F. Humoral immunity conferred by HDCS rabies vaccine Merieux administered after exposure; 151 cases with and without specific immunoglobulins of human origin, preliminary communication. Joint WHO/IABS. Symposium on the standardization of rabies vaccines for human use produced in tissue cultures, Marburg 1977, Germany. Develop Biol Standard 1978;40:159.